Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339029 | 1.00 | RIPK1 (0.44) | RIPK1FFAR4EIF2AK4ACACBHRH3 | |
| SCHEMBL30339429 | 0.89 | RIPK1 (0.41) | RIPK1EIF2AK4ACACBPTPN11 | |
| SCHEMBL25257034 | 0.89 | RIPK1 (0.41) | RIPK1EIF2AK4ACACBPTPN11 | |
| SCHEMBL25816949 | 0.85 | RIPK1 (0.42) | RIPK1EIF2AK4PTPN11MAPT | |
| SCHEMBL30338804 | 0.85 | RIPK1 (0.42) | RIPK1EIF2AK4PTPN11MAPT | |
| SCHEMBL25817044 | 0.85 | RIPK1 (0.42) | RIPK1EIF2AK4 | |
| SCHEMBL30338712 | 0.84 | RIPK1 (0.42) | RIPK1EIF2AK4ACACBPTPN11LMNA | |
| SCHEMBL25297333 | 0.84 | RIPK1 (0.42) | RIPK1EIF2AK4ACACBPTPN11LMNA | |
| SCHEMBL30338714 | 0.84 | RIPK1 (0.42) | RIPK1EIF2AK4ACACBPTPN11LMNA | |
| SCHEMBL25817000 | 0.82 | RIPK1 (0.41) | RIPK1EIF2AK4PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | RIPK1 1/4885FFAR4 1153/4885EIF2AK4 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.